Product Information
LABETALOL HCL 300 MG TABLET is a generic product labeled by Major Pharmaceuticals, priced at $0.2146 per EA under NDC 00904745361. Its NADAC has been published 84 times since Feb 26, 2025.
FDA first approved this application on Jun 20, 2018. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
300 mg/1
Manufacturer
Major PharmaceuticalsNDC
00904745361
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
LABETALOL HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA209603FDA Approved
6/20/2018
TE Code
AB
On Market Since
10/8/2024
Pharmacological Classes
Price Statistics
The NADAC for LABETALOL HCL 300 MG TABLET has been published 84 times since Feb 26, 2025, and over the history we have for it it has risen 9.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.2146 per EA |
|---|---|
| All-time high | $0.2157 (Sep 16, 2026) |
| All-time low | $0.1954 (Feb 26, 2025) |
| 52-week high | $0.2157 |
| 52-week low | $0.2041 |
| Median price | $0.2057 |
| Average price | $0.2059 |
| Largest weekly change | +4.2% (Aug 19, 2026) |
| Weeks tracked | 84 |
| Tracking since | Feb 26, 2025 |
Generic Alternatives
The matcher finds 11 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 5% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Major Pharmaceuticals manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Labetalol Hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
beta-Adrenergic Blocker class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of LABETALOL HCL 300 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for LABETALOL HCL 300 MG TABLET, manufactured by Major Pharmaceuticals, is $0.2146 per EA (NDC 00904745361), effective Sep 30, 2026.
How has the price of LABETALOL HCL 300 MG TABLET changed over time?
Over the history we have for it, the NADAC for LABETALOL HCL 300 MG TABLET has risen 9.8%. It has been tracked across 84 weekly CMS publications since Feb 26, 2025.
What are the highest and lowest recorded NADAC prices for LABETALOL HCL 300 MG TABLET?
Since Feb 26, 2025, the NADAC for LABETALOL HCL 300 MG TABLET has ranged from a low of $0.1954 (Feb 26, 2025) to a high of $0.2157 (Sep 16, 2026), with a median of $0.2057 per EA.
Are there cheaper alternatives to LABETALOL HCL 300 MG TABLET?
Yes. 11 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, LABETALOL HCL 300 MG TABLET, is $0.2041 per EA — about 5% below LABETALOL HCL 300 MG TABLET.
Who manufactures LABETALOL HCL 300 MG TABLET?
LABETALOL HCL 300 MG TABLET (NDC 00904745361) is labeled by Major Pharmaceuticals, and CMS classifies it as a generic product.